Univariate and multivariate Cox proportional hazard regression in EBV+ DLBCL-NOS (n = 70)
| Variable . | Univariate analysis . | Multivariate analysis . | ||||||
|---|---|---|---|---|---|---|---|---|
| PFS . | OS . | PFS . | OS . | |||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| ECOG-PS ≥ 2 | 16.26 (4.32, 61.28) | <.001 | 15.91 (3.75, 67.61) | <.001 | — | — | ||
| Age >50 y | 10.74 (2.72, 42.43) | < .001 | 9.93 (2.34, 41.09) | .002 | 14.01 (2.34, 83.97) | .004 | 12.41 (1.65, 93.54) | .014 |
| HLH | 7.35 (3.11, 17.37) | < .001 | 8.31 (3.44, 20.06) | <.001 | 5.78 (2.35, 14.23) | < .001 | 6.09 (2.42, 15.30) | < .001 |
| aaIPI ≥ 2 | 6.68 (1.57, 28.46) | .010 | 12.22 (1.64, 91.18) | .015 | 3.03 (0.68, 13.47) | .14 | 5.76 (0.75, 44.53) | .093 |
| B symptoms | 5.38 (1.28, 22.68) | .022 | 4.78 (1.13, 20.27) | .034 | — | — | ||
| Clinical stage III-IV | 3.45 (1.04, 11.44) | .043 | 4.68 (1.11, 19.84) | .036 | — | — | ||
| Extranodal disease | 2.79 (1.30, 5.99) | .008 | 2.74 (1.23, 6.13) | .014 | — | — | ||
| Lymphopenia | 2.47 (0.83, 7.36) | .103 | 3.18 (0.92, 10.90) | .066 | — | — | ||
| LDH elevated | 2.07 (0.71, 6.06) | .185 | 2.69 (0.79, 9.11) | .112 | — | — | ||
| Latency type III | 2.09 (0.74, 5.89) | .160 | 2.13 (0.71, 6.39) | .180 | — | — | ||
| Female | 0.95 (0.47, 1.94) | .900 | 1.14 (0.55, 2.38) | .720 | — | — | ||
| PD-L1 H-score > 150 | 0.68 (0.27, 1.73) | .420 | 0.60 (0.23, 1.56) | .290 | — | — | ||
| Polymorphic | 0.60 (0.29, 1.25) | .170 | 0.62 (0.29, 1.34) | .220 | — | — | ||
| Variable . | Univariate analysis . | Multivariate analysis . | ||||||
|---|---|---|---|---|---|---|---|---|
| PFS . | OS . | PFS . | OS . | |||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| ECOG-PS ≥ 2 | 16.26 (4.32, 61.28) | <.001 | 15.91 (3.75, 67.61) | <.001 | — | — | ||
| Age >50 y | 10.74 (2.72, 42.43) | < .001 | 9.93 (2.34, 41.09) | .002 | 14.01 (2.34, 83.97) | .004 | 12.41 (1.65, 93.54) | .014 |
| HLH | 7.35 (3.11, 17.37) | < .001 | 8.31 (3.44, 20.06) | <.001 | 5.78 (2.35, 14.23) | < .001 | 6.09 (2.42, 15.30) | < .001 |
| aaIPI ≥ 2 | 6.68 (1.57, 28.46) | .010 | 12.22 (1.64, 91.18) | .015 | 3.03 (0.68, 13.47) | .14 | 5.76 (0.75, 44.53) | .093 |
| B symptoms | 5.38 (1.28, 22.68) | .022 | 4.78 (1.13, 20.27) | .034 | — | — | ||
| Clinical stage III-IV | 3.45 (1.04, 11.44) | .043 | 4.68 (1.11, 19.84) | .036 | — | — | ||
| Extranodal disease | 2.79 (1.30, 5.99) | .008 | 2.74 (1.23, 6.13) | .014 | — | — | ||
| Lymphopenia | 2.47 (0.83, 7.36) | .103 | 3.18 (0.92, 10.90) | .066 | — | — | ||
| LDH elevated | 2.07 (0.71, 6.06) | .185 | 2.69 (0.79, 9.11) | .112 | — | — | ||
| Latency type III | 2.09 (0.74, 5.89) | .160 | 2.13 (0.71, 6.39) | .180 | — | — | ||
| Female | 0.95 (0.47, 1.94) | .900 | 1.14 (0.55, 2.38) | .720 | — | — | ||
| PD-L1 H-score > 150 | 0.68 (0.27, 1.73) | .420 | 0.60 (0.23, 1.56) | .290 | — | — | ||
| Polymorphic | 0.60 (0.29, 1.25) | .170 | 0.62 (0.29, 1.34) | .220 | — | — | ||